Australia's most trusted
source of pharma news
Friday, 01 August 2025
Posted 30 July 2025 PM
The rollercoaster ride for Sarepta Therapeutics continues with the FDA recommending a voluntary hold on the company's gene therapy Elevidys be lifted, after an investigation into a fourth death.
The FDA's decision came a day after it announced it was investigating a fresh patient death, that of an eight-year-old Brazilian boy who'd been treated with the gene therapy for Duchenne muscular dystrophy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.